

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO. 053466-0365

Applicant: Hiroaki ITO et al.

Title: A PREVENTIVE OR THERAPEUTIC AGENT FOR

INFLAMMATORY BOWEL DISEASE COMPRISING IL-6

ANTAGONIST AS AN ACTIVE INGREDIENT

Appl. No.: 10/677,227

Filing Date: 10/03/2003

Examiner: Prema Mertz

Art Unit: 1646

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Appl. No. 10/677,227

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Document B1 is an English counterpart of Document B2.

English translations of the foreign-language documents are not readily available. However, the absence of such translations does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

tydw 18Mal

Date March 13, 2006

**FOLEY & LARDNER LLP** 

Customer Number: 22428

Telephone:

(202) 672-5571

Facsimile:

(202) 672-5399

Stephen B. Maebius Attorney for Applicant

Registration No. 35,264

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known THE STATEMENT BY APPLICANT **Application Number** 10/677,227 10/03/2003 MAR 1 4 2006 Filing Date Hiroaki ITO First Named Inventor Date Submitted: Group Art Unit 1646 **Examiner Name** as many sheets as necessary) Prema MERTZ 053466-0365 of 1 Attorney Docket Number

Examiner Initials*	Cite No.1	U.S. Patent Document		U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	B1	5,888,510		Kishimoto et al.	03/30/1999	

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where	
		Office Nilmher		Kind Code <sup>5</sup> ( <i>if known</i> )		MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		JP	8-208514		Chugai Pharmaceutical Co. Ltd.; Kishimoto CHUZO	08/13/1996		Abs
	В3	wo	96/00081	A1	Immunex Corporation	01/04/1996		
	B4	wo	97/38104	А	Applied Research Systems Ars Holding N. V.	10/16/1997		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1					
	B5	IGAKU, Vol. 51, No. 10, 1996, pgs. 111-121, with Partial Translation.				
	B6	Jpn. J. Clin. Immun., Vol. 20, No. 2, 1997, pgs. 87-94.				

Examiner Signature	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.